# iShares Healthcare Innovation UCITS ETF (DRDR)

**Page:** https://fundology.uk/fund/drdr · ISIN IE00BYZK4776

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 13/11/2026, DRDR (iShares Healthcare Innovation UCITS ETF, ISIN IE00BYZK4776) closed at £8.43 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 13/11/2026 its total return was +15.9%, or −9.5% after UK CPIH inflation.

## Summary

iShares Healthcare Innovation UCITS ETF is an exchange-traded fund (ETF) from iShares, launched in 2016. It tracks the iSTOXX FactSet Breakthrough Healthcare. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£8.43** (13/11/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | DRDR |
| ISIN | IE00BYZK4776 |
| Also listed as | HEAL (London Stock Exchange, US dollars), 2B78 (Xetra, euros) |
| Category | Healthcare |
| Type | ETF |
| Provider | iShares |
| Tracks | iSTOXX FactSet Breakthrough Healthcare |
| Income | Accumulating |
| Ongoing charge | 0.40% a year (£40 per £10,000) |
| Fund size | £1.3bn |
| Launched | 2016 |
| Domicile | Ireland |
| UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 12/09/2016 |

## Past returns (periods to 13/11/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +30.35% | +25.73% | income reinvested |
| 3 years | +67.43% | +51.27% | income reinvested |
| 5 years | +15.92% | -9.52% | income reinvested |

Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund): 2022 −14.9%, 2023 −2.5%, 2024 +4.2%, 2025 +8.4%; 2026 to 13/11/2026 +26.2%. Returns of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +30.2%; to 30/09/2025: +5.4%; to 30/09/2024: +8.2%; to 30/09/2023: −10.5%; to 30/09/2022: −15.2%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2022 | -14.9% | -22.1% | Price |
| 2023 | -2.5% | -6.4% | Price |
| 2024 | +4.2% | +0.7% | Price |
| 2025 | +8.4% | +4.6% | Price |
| 2026 to 13/11/2026 | +26.2% | +22.2% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 16.80% | -10.39% |
| 3 years | 16.15% | -20.57% |
| 5 years | 17.50% | -32.16% |

## Largest fall

Volatility of iShares Healthcare Innovation UCITS ETF in pounds, annualised from weekly returns to 13/11/2026: 16.8% over 1 year, 16.2% over 3 years, 17.5% over 5 years. Largest fall in the price of iShares Healthcare Innovation UCITS ETF since November 2021, in pounds: −30.9% from 19/11/2021 to 27/10/2023. The lowest 12-month return of iShares Healthcare Innovation UCITS ETF in pounds (price, with income reinvested in the fund) since January 2021 was −27.2% (12 months to 17/06/2022); the highest was +38.4% (12 months to 25/09/2026). On 13/11/2026 the price of iShares Healthcare Innovation UCITS ETF was 0.8% below its highest weekly close since November 2021 (30/10/2026), in pounds.

## Charges compared with similar funds

Ongoing charge of iShares Healthcare Innovation UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.40%** per year
- Stocks and shares ISA eligible: usually (check with your platform)
- SIPP eligible: usually (check with your provider)
- ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify.

## What it holds

As of 06/11/2026, DRDR holds 198 positions, according to its published holdings. The largest is Moderna at 6.25% of the fund; the ten largest make up 21.7%.

### Top holdings

Largest positions (as of 06/11/2026), as a percentage of the whole fund:

| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | Moderna | [MRNA](https://fundology.uk/stock/MRNA) | 6.25% |
| 2 | Genmab | [GMAB](https://fundology.uk/stock/GMAB) | 2.48% |
| 3 | Iqvia | [IQV](https://fundology.uk/stock/IQV) | 1.71% |
| 4 | Revvity | [RVTY](https://fundology.uk/stock/RVTY) | 1.69% |
| 5 | Natera | [NTRA](https://fundology.uk/stock/NTRA) | 1.64% |
| 6 | Celltrion | [068270](https://fundology.uk/stock/068270) | 1.63% |
| 7 | Charles River Laboratories International | [CRL](https://fundology.uk/stock/CRL) | 1.59% |
| 8 | Amgen | [AMGN](https://fundology.uk/stock/AMGN) | 1.57% |
| 9 | Roivant Sciences | [ROIV](https://fundology.uk/stock/ROIV) | 1.57% |
| 10 | Gilead Sciences | [GILD](https://fundology.uk/stock/GILD) | 1.56% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.

### By sector

As published for the fund, as of 06/11/2026.

| Sector | Weight |
|---|---|
| Health Care | 98.1% |
| Information Technology | 1.0% |
| Industrials | 0.5% |
| Cash and derivatives | 0.2% |
| Real Estate | 0.2% |

### By country

As published for the fund, as of 06/11/2026.

| Country | Weight |
|---|---|
| United States | 69.6% |
| Switzerland | 5.5% |
| Japan | 4.5% |
| South Korea | 3.9% |
| Denmark | 3.4% |
| Belgium | 2.6% |
| Germany | 1.9% |
| United Kingdom | 1.6% |
| Other countries | 7.0% |

### By type of asset

Added up from the fund’s published holdings, as of 06/11/2026.

| Type of asset | Weight |
|---|---|
| Equity | 99.8% |
| Cash and money market | 0.2% |

The 194 holdings on record (of 198 reported): https://fundology.uk/fund/drdr/holdings

## Questions people ask

**What is the ongoing charge of DRDR?**

The ongoing charge of DRDR is 0.40% a year — about £40 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of iShares Healthcare Innovation UCITS ETF 0.40% a year. Compared on 14/11/2026, 7 of the 28 other healthcare funds charge more, 2 the same and 19 less (share classes counted once).

**What does DRDR track?**

DRDR tracks the iSTOXX FactSet Breakthrough Healthcare.

**Is DRDR accumulating or distributing?**

DRDR is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

**What is the ISIN of DRDR?**

The ISIN of DRDR is IE00BYZK4776. An ISIN identifies one exact share class of a fund; DRDR is its ticker on the London Stock Exchange. The same share class is also listed as HEAL (London Stock Exchange, US dollars) and 2B78 (Xetra, euros).

**What does DRDR hold?**

As of 06/11/2026, DRDR holds 198 positions, according to its published holdings. The largest is Moderna at 6.25% of the fund; the ten largest make up 21.7%. Its ten largest holdings are Moderna (6.25%), Genmab (2.48%), Iqvia (1.71%), Revvity (1.69%), Natera (1.64%), Celltrion (1.63%), Charles River Laboratories International (1.59%), Amgen (1.57%), Roivant Sciences (1.57%) and Gilead Sciences (1.56%).

**What were DRDR’s returns in each of the last five years?**

Calendar-year returns of DRDR in pounds (price, with income reinvested in the fund): 2022 −14.9%, 2023 −2.5%, 2024 +4.2%, 2025 +8.4%; 2026 to 13/11/2026 +26.2%. Past performance is not a guide to future returns.

**How has DRDR done after inflation?**

Over the five years to 13/11/2026 DRDR’s total return was +15.9%, or −9.5% after UK CPIH inflation. Past performance is not a guide to future returns.

## Fund documents

- [Fund page at iShares](https://www.ishares.com/uk/individual/en/products/284216/ishares-healthcare-innovation-ucits-etf-usd-acc)
- [Key investor information document (KIID)](https://www.ishares.com/gls-download/literature/kiid/ucits_kiid-ishares-healthcare-innovation-ucits-etf-usd-acc-gb-ie00byzk4776-en.pdf)
- Links checked 12/10/2026.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.